PDS BiotechnologyPDSB
PDSB
About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Employees: 25
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,108% more call options, than puts
Call options by funds: $157K | Put options by funds: $13K
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
0.42% less ownership
Funds ownership: 11.75% [Q3] → 11.33% (-0.42%) [Q4]
9% less funds holding
Funds holding: 56 [Q3] → 51 (-5) [Q4]
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
58% less capital invested
Capital invested by funds: $16.5M [Q3] → $6.92M (-$9.6M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$21
1,554%
upside
Avg. target
$21
1,554%
upside
High target
$21
1,554%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 18% 1-year accuracy 75 / 411 met price target | 1,554%upside $21 | Buy Reiterated | 13 Mar 2025 |
Financial journalist opinion
Based on 8 articles about PDSB published over the past 30 days
Neutral
GlobeNewsWire
7 hours ago
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune ® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (“IND”) application filed in January 2025 to evaluate a combination of Versamune® MUC1 (formerly PDS0103), its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma (“mCRC”) in patients who failed previous treatment.
Neutral
GlobeNewsWire
2 days ago
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.
Neutral
GlobeNewsWire
6 days ago
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial
Positive
Proactive Investors
1 week ago
EMV Capital portfolio company PDS Biotechnology raises $11mln
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million.
Neutral
GlobeNewsWire
2 weeks ago
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of the Company.
Neutral
GlobeNewsWire
2 weeks ago
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor naïve patients; Historically published result is 11-24% PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology.
Neutral
GlobeNewsWire
2 weeks ago
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
Neutral
GlobeNewsWire
3 weeks ago
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B.
Neutral
GlobeNewsWire
3 months ago
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech.
Neutral
GlobeNewsWire
3 months ago
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation
Charts implemented using Lightweight Charts™